SCO-792 is under clinical development by Scohia Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SCO-792’s likelihood of approval (LoA) and phase transition for Non-Alcoholic Steatohepatitis (NASH) took place on 16 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SCO-792 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SCO-792 is under development for the treatment of obesity subjects with type 2 diabetes, albuminuria, diabetic nephropathy, non-alcoholic steatohepatitis (NASH), chronic kidney disease and obesity. It is administered orally. The drug candidate targets enteropeptidase enzyme.
Scohia Pharma overview
Scohia Pharma is a bio-pharmaceutical company which develops and commercializes novel therapeutics for metabolic, cardiovascular and renal diseases. The company product pipeline includes SCO-272, SCO-792, SCO-094, SCO-267, SCO 240, SCO 006 and SCO 116. Its SCO-272 candidates acts as an an inhibitor for the treatment of hypertension, SCO-792 is an oral drug for the treatment of obesity, SCO-094 is an injectable peptide for the treatment of diabetes and SCO-267 is an oral agonist. Scohia Pharma services comprises pharmacological research, synthetic research and clinical development, among others. It serves in the therapeutic areas of blood glucose, blood pressure and lipids. Scohia Pharma is headquartered in Fujisawa, Kanagawa, Japan.
Quick View SCO-792 LOA Data
|Highest Development Stage|